Navigation Links
NIH-supported study finds novel pathway may open doors for new blood pressure treatments
Date:6/21/2010

Researchers have found that increasing certain proteins in the blood vessels of mice, relaxed the vessels, lowering the animal's blood pressure. The study provides new avenues for research that may lead to new treatments for hypertension.

"The paper demonstrates that cytochrome P450 plays an important role in the management of high blood pressure, a disease of enormous public health concern," said Darryl Zeldin, M.D., acting clinical director of the National Institute of Environmental Health Sciences (NIEHS) and senior author on the paper.

According to the Centers for Disease Control and Prevention, about 1 in 3 adults in the United States has high blood pressure, which increases the risk for heart disease and stroke, the first and third leading causes of death in the United States.

The study, published online in The FASEB Journal, was conducted by researchers at NIEHS who teamed with investigators at the University of North Carolina at Chapel Hill (UNC), Medical College of Wisconsin, Milwaukee, and Oregon Health and Science University, Portland.

The researchers created animal models that had a human cytochrome P450 (CYP450 or P450) in the cells that line their blood vessels. The mice with the P450 generated more substances called epoxyeicosatrienoic acids or EETs, known for their role in protecting the cardiovascular system. EETs relax and dilate the blood vessels and fight inflammation.

"We found that when the animals were exposed to substances known to increase blood pressure, the animals with the P450 had lower blood pressure and less damage to the kidneys compared to normal mice," said Craig R. Lee, Pharm.D., Ph.D., assistant professor at UNC and lead author on the paper. "We hope that these studies will advance the development of new treatments for high blood pressure."

"This is a great example of a basic finding that improves our understanding of a metabolic pathway that can be used to develop improved treatments for those suffering from a common disease like hypertension," said Linda Birnbaum, Ph.D., director of the NIEHS and the National Toxicology Program.


'/>"/>

Contact: Robin Mackar
rmackar@niehs.nih.gov
919-541-0073
NIH/National Institute of Environmental Health Sciences
Source:Eurekalert

Related biology news :

1. From bark to bedside: Study looks at canine cancer genes, human health impact
2. LSU professor uses volcanic emissions to study Earths atmospheric past
3. Robot submarine patrols Lake Michigan for climate-change study
4. New study documents use of hormone progesterone in simple microscopic aquatic animals
5. WHOI joins consortium to study, minimize effects of Gulf Oil spill
6. Study of severe asthma using CT scans
7. Study shows adding UV light helps form Missing G of RNA building blocks
8. Suspended animation protects against lethal hypothermia, study shows
9. UAB study confirms link between depression, abdominal obesity
10. UMCES Horn Point Laboratory scientists to study oil spill effects in Gulf of Mexico
11. CoLucid Pharmaceuticals, Inc. announces study data documenting oral efficacy of lasmiditan (COL-144), a selective 5-HT1F receptor agonist, in the treatment of acute migraine attacks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/16/2017)... 2017 CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made ... ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity ... Used combined in one project, multi-biometric ... ...
(Date:3/7/2017)... 7, 2017   HireVue , the leading provider ... identify the best talent, faster, today announced the additions ... (CSO) and Diana Kucer as Chief Marketing ... executive team poised to drive continued growth in the ... year of record bookings in 2017. "Companies ...
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
Breaking Biology News(10 mins):
(Date:3/22/2017)... 2017 /PRNewswire/ - FACIT announced a seed stage ... a start-up created by FACIT focused on developing ... combined with non-dilutive capital, achieves a targeted $3.0M ... enables Propellon to accelerate the nomination of a ... and/or entering a strategic partnership for clinical trials ...
(Date:3/22/2017)... ... March 21, 2017 , ... ... acquire information on the desired increase and/or decrease in antibody-dependent cellular cytotoxicity or ... N-glycosylation profiling of therapeutic antibodies. , To meet this demand, the team ...
(Date:3/22/2017)... , ... March 21, 2017 , ... Functional near-infrared spectroscopy ... is being explored as a way to track the brain’s response to acute pain ... activation by cold pressor test ,” published today in the journal Neurophotonics , ...
(Date:3/22/2017)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII), a clinical-stage ... unmet medical needs, today announced Alexey Eliseev ... at the 5th Annual Cancer BioPartnering & Investment ... present to and meet with thought leaders from ... as well as institutional investors. This event will ...
Breaking Biology Technology: